Background. Although clinical guidelines are available for the management of asthma, this health condition is still poorly managed in many countries. Objectives. To assess the effects of a Pharmacy Management Service (PharMS) on asthma control of adult patients. Methods. This study comprised of a cluster randomised controlled trial (RCT) that was conducted from April 2014 to July 2015 at four government health clinics. The control participants received usual pharmacy service, while the intervention participants were recruited into the PharMS. Each participant was monitored for 6 months, and the outcome measures included asthma control using the Asthma Control Test (ACT), inhaler technique using a checklist and medication adherence using the Malaysian Medication Adherence Scale. Results. A total of 157 participants were recruited: 77 in the control and 80 in the intervention group. At the end of the study, 90% of the intervention participants achieved well-controlled asthma compared to 28.6% in the control group (P < 0.001). The differences in the proportion of participants with correct inhaler technique was also significant, with an adjusted effect size of 0.953 (P < 0.001). In addition, the intervention participants showed significantly higher medication adherence than the control group (92.5% versus 45.5%, P < 0.001). The Generalised Estimated Equation analysis further confirmed that the PharMS (P < 0.001) was significantly related to an improvement in the ACT scores. Conclusion. A community-based asthma management program, the PharMS, that provided asthma education and skill training by a trained pharmacist, resulted in positive and significant improvements in clinical and management outcomes of adult asthma patients.
Introduction
Although clinical guidelines for the management of asthma are available in many countries, this health condition is still poorly managed. Asthma affected 334 million people around the world and the years lived with disability was found to be 13 835 in year 2010, with an increase of 27.7% compared to year 1990 (1) . This indicates suboptimal management of asthma and generally low adherence to clinical guidelines (2, 3) . Data from the National Health and Morbidity Survey showed that the prevalence of asthma in Malaysia was 6.4%, with an estimated 4.5% among adults and 7.1% among children (4) .
Current guidelines define asthma control as absence or minimization of daytime and nocturnal symptoms; reduction of exacerbations; minimal or no rescue therapy required; normal lung function; and no limitation of activities. (5, 6) . Factors that contributed to uncontrolled asthma included poor adherence to prescribed medications, wrong technique of using an inhaler and lack of patient education (7) (8) (9) .
Some studies which investigated the effects of pharmaceutical care (PC) on asthma patients showed a reduction in chronic symptoms, improvements in lung function, patient-related outcomes (such as quality of life and asthma knowledge), asthma severity and drug utilization which included medication adherence and inhalation technique (7) (8) (9) (10) .
In Malaysia, an ambulatory care service, Respiratory Medication Therapy Adherence Clinic (RMTAC), has been established by pharmacists in collaboration with other healthcare providers. The aim of this service is to help patients manage their asthma and chronic obstructive pulmonary disease (11) . However, such service has been implemented only in some of the government hospitals and only a few public health clinics. The hypothesis was that a Pharmacy Management Service (PharMS), which focussed on medication adherence and the correct technique of using an inhaler by adult asthma patients as well as providing patients with adequate knowledge of asthma, would result in the improvement of asthma control in these patients. Therefore, this study comprised of a cluster randomised controlled trial (RCT) to assess the effects of a PharMS on adult patients with asthma, which would ultimately affect the frequency of asthma-related symptoms.
Methods

Study design
This study comprised of a cluster RCT where data collection was conducted from 1st April 2014 to 30th July 2015. Government health clinics located in the districts of Muar and Ledang were the units of randomisation. These two districts are situated in the state of Johor which is located at the southern part of Malaysia, towards the north of Singapore. The health clinics with low patient workload (<2000 prescriptions/month) and those that declined to participate were excluded. The remaining two health clinics from the district of Muar and another two clinics from the district of Ledang were assigned at random, using the IBM Statistical Package for the Social Sciences (SPSS) version 21.0 (IBM Corporation, Armonk, NY), to either the control or the intervention (PharMS) sites such that each district had a control and an intervention site ( Figure 1 ).
Study Population
Included were patients aged 21 years and older, with physiciandiagnosed asthma and were treated for asthma with controller metered dose inhalers (MDIs) at selected health clinics. Patients who were using aerochambers; had participated or were participating in other pharmacy counselling programmes; diagnosed with other significant pulmonary disease such as Chronic Obstructive Pulmonary Disease (COPD) or carcinoma and could not communicate in Malay, English, Mandarin or Cantonese were excluded. Patients who have smoking history of more than 10 packs of cigarettes per year were also excluded from the study to avoid the inclusion of patients with COPD (12) .
Sample size
The sample size for the study was calculated using the Power and Sample Size Calculation software version 3.0.43 by Dupont and Plummer (Vanderbilt University, Tennessee), based on the comparison between two means. In order to detect a difference of 0.5 in mean Asthma Control Test (ACT) score (with standard deviation estimated as 0.74) between the control and the intervention groups (13), with 80% power of detection and an alpha error of 0.05, at least 70 participants would be required. The sample size was then adjusted according to standard criteria for cluster RCT, inflated by a Design Effect (DE) which was calculated based on 1 + (n − 1) ICC, where n is the average cluster size and ICC is an estimate of intra-cluster correlation coefficient (14) . Since four study sites would be involved, the average cluster size would be 18. Assuming that the ICC was 0.05 (9) , the DE would be 1.85. This would then give an adjusted sample size of 130. Taking into account an attrition rate of 20%, a total of at least 156 patients and 4 clinics should be included in the study.
Outcome measures
Asthma control
Asthma control was assessed based on the ACT scores. The ACT is a validated instrument that is available in many languages (15) (16) (17) (18) . The total ACT scores range from 5 to 25 (the higher the score, the better control) and are classified into three categories: very poorly controlled asthma (scores of 5-15), not well controlled (scores of 20) and well-controlled asthma (21-25) (6).
The peak expiratory flow rate (PEFR) and the usage of reliever medication were also assessed. The PEFR was measured using a peak flow meter in L/min. The higher the PEFR, the better the lung function with lesser expiratory airflow limitation (5) . In addition, the PEFR ratio in this study indicates to what extent the patient meets his or her expected PEFR, according to his or her gender, age and height. Personal best PEFR rather than expected PEFR has been recommended for the monitoring of lung function (5) . However, this could not be performed in the present study, as a majority of patients could not afford a peak flow meter to monitor their own PEFR at home. They were also not able to visit the clinic daily to determine their personal best PEFR. Therefore, the expected PEFR was used in the present study.
The usage of reliever medication in this study, MDI Salbutamol 100 µg/puff (200 doses per MDI), was calculated based on the number of doses left in the MDI, using the following equation: The number of doses left in the last MDI was estimated based on the number of puffs being released after it was returned to the researchers at the end of the study.
Inhaler technique
The technique of using an MDI was assessed based on an Inhaler Technique Checklist which consisted of six steps as recommended by the Global Initiative for Asthma (GINA) Patient Guide. (19) . Patients were observed at baseline, month 3 and 6 by study staff to document whether every step was preformed correctly. Every step should be performed correctly to be considered as the correct inhaler technique.
Medication adherence
Medication adherence was measured using the Malaysian Medication Adherence Scale (MALMAS). The MALMAS is a validated 8-item assessment tool for assessing medication adherence. A score of less than 6 indicates 'non-adherence', while a score of 6-8 indicates 'adherence' (20) .
Patients' knowledge on asthma medications
Patients' knowledge on each asthma medication that they were using was assessed in terms of dose, frequency, indication and method of administration. Each of these 4 items was assessed separately for each asthma medication used by the participants, and the responses were classified as 'correct' or 'wrong' answers (11).
Data collection procedure
Asthma patients who met the inclusion criteria from the selected health clinics were approached to participate in the study. Patients were recruited consecutively from April 2014 to February 2015 at each of the health clinics, and all patients gave their informed written consent.
The outcome measures for both control and intervention groups were assessed at month 0, 3 and 6 of the study. The control participants received usual pharmacy service which was the dispensing of medications with brief instructions on how to take the medications, whereas PC was provided to the intervention participants who were enrolled into the PharMS. Pharmacist interventions were specifically tailored to the patient's current asthma control based on the Global Initiative for Asthma guidelines (21) .
Participants from the control sites had no contact with the pharmacist who provided PC to the participants at the intervention sites. All data obtained from the intervention and control sites were collected by an enumerator who was a pharmacy staff working at the study sites. The enumerator was not aware of which study site was the control or intervention site and which districts or clinics were involved in the study. Since the study sites selected were more than 10 km from each other, contamination between control and intervention participants would thus be minimised. The participants were not told specifically whether they were in the control or intervention group. Nevertheless, in order to prevent any resentful demoralization among the control participants, all participants were provided with same care by the pharmacist after completion of the study.
Pharmacy Management Service
Participants in the intervention (PharMS) group were provided with PC by a pharmacist who had been trained to provide ambulatory care to the communities.
PharMS was developed based on literature review and the services provided by pharmacists in the RMTAC which has been implemented in some government hospitals and clinics in Malaysia since 2010. PharMS consisted of (i) education on asthma (including signs and symptoms, trigger factors, consequences of uncontrolled asthma) with the aid of a booklet which was specially prepared for asthma patients; (ii) counselling sessions with physical demonstrations on the correct technique of using inhalers; (iii) counselling sessions on participants' medications, including methods of administration, possible side effects and precautions; (iv) emphasis on the importance of medication adherence; (v) identification of any PC issues encountered by the patients; (vi) recommendations to the physicians on any changes related to the participants' medications, based on the GINA guidelines (updated year 2013) (21) and (vii) provision of a Written Asthma Action Plan which had been counterchecked by the Research Team (consisted of two pharmacists and two family medicine specialists).
A total of five counselling sessions were conducted: four faceto-face sessions at month 0, 1, 3 and 6, after assessment of the outcome measures, and one session was via telephone call at month 2 ( Figure 1 ). Each counselling session took about 20-30 minutes. All interventions were conducted by the same pharmacist at the two intervention clinics to ensure consistency.
Statistical analysis
Statistical analyses were performed using the IBM Statistical Package for the Social Sciences (SPSS) for Windows, version 21.0 (IBM Corporation, Armonk, NY). Any association between categorical variables was analysed using Pearson chi-square test. The differences between continuous variables were analysed using independent t-tests (which were expressed as mean and standard deviation). A P value of less than 0.05 was considered as statistically significant.
The changes in ACT score, PEFR at visit and PEFR ratio between the study visits were analysed using repeated measures analysis of variance, which were expressed as F statistic and degrees of freedom (DF). The effect size was calculated for each outcome variable in order to quantify the difference between control and intervention groups. An effect size is classified as small (d = 0.2), medium (d = 0.5) and large (d > 0.8) (23) . The results obtained (F statistic, t statistic, chi-square, P value and effect size) were adjusted for clustering effect.
The Generalised Estimating Equations (GEE) analysis was used to determine factors that might be associated with the change in the ACT score. This analysis accounted for the clustering of participants within clinics and was adjusted by covariates that could affect the ACT score (control or intervention group, ethnic group, gender, marital status, education level, age, body mass index, living area, smoking status, number of years since diagnosed with asthma, PEFR at visit, expected PEFR, PEFR ratio, inhaler technique, medication adherence, knowledge in dose, frequency, indication and method of administration).
Results
A total of 79 and 92 participants were enroled in the control and intervention groups, respectively. However, 2 participants from the control and 12 from the intervention group were lost during the follow-up period between baseline and month 3 assessment. The remaining 157 participants completed the study: 77 in the control and 80 in the intervention group (Figure 1 ). Characteristics of participants who completed the 6-month study period are presented in Table 1 . At baseline, there was no significant difference in demographic and clinical characteristics between participants in the control and intervention groups.
Outcome measures
Asthma control
At the end of the 6-month study period, the mean ACT score of the intervention group was significantly higher than the control group (Table 2) , with a large adjusted effect size of 0.909, F (DF) = 32.041 (1; 155); P < 0.001. The mean difference in the ACT score increased from baseline (1.027) to 4.646 at month 3 and to 4.660 at month 6. In addition, the proportion of participants with controlled asthma in the intervention group increased significantly from baseline (36.3%) to 78.8% at month 3 and 90.0% at month 6 of the study, whereas this proportion in the control group remained between 26% and 28.6%. This resulted in a large adjusted effect size of 1.051 (Table 3) .
Although the mean differences in the PEFR at visit and the PEFR ratio between the intervention and control groups increased from baseline to month 3 and 6, these were not statistically significant and the effect sizes were small ( Table 2) .
The intervention participants used significantly less reliever medications than the control participants, with a mean difference of −3.61, adjusted t (95% confidence interval [CI]) = −4.943 (−4.467, −2.743), P<0.001, and a medium effect size of 0.789 (Table 2) .
Inhaler technique
Improvement in inhaler technique was observed in both control and intervention groups (Table 3 ). The proportion of control participants with correct inhaler technique increased from 10.4% at baseline to 32.5% at month 3 and to 26.0% at month 6. The proportion of intervention participants with correct inhaler technique increased from baseline (6.3%) to 62.5% at month 3 and to 86.3% at month 6. The differences in the proportion of participants with correct inhaler technique was significant at month 3 and 6 (adjusted effect size = 0.435 and 0.953, respectively).
Medication adherence
Although both control and intervention groups showed an improvement in medication adherence throughout the study, a significantly higher proportion of participants in the intervention group were adherent to their medications at month 3 and 6 of the study compared to the control group (adjusted effect size = 0.508 and 0.707, respectively; Table 3 ).
Patient's knowledge on asthma medications
The percentage of intervention participants who knew about the dose, frequency and method of administration of their medications at month 6 of the study was significantly higher than that of the control group (Table 3) . However, the effect sizes for knowledge on frequency and method of administration were small and medium only (0.334 and 0.796, respectively). The effect size for knowledge on indication was not significant.
GEE analysis
Nineteen potential factors, adjusted for clustering effect, which could be associated with asthma control (based on the ACT score), were included in the GEE analysis. Factors with significant interactions were excluded from the subsequent GEE analysis for ACT score. After accounting for confounding factors and interactions, the GEE analysis showed that the PharMS (Wald chi-square = 46.921; regression coefficient, B = 2.930; 95% CI: 2.092, 3.769; P < 0.001) was significantly related to an improvement in the asthma control (Table 4) .
Discussion
This study was most probably the first cluster RCT which was conducted in Malaysia to evaluate the effects of a PharMS on adults with asthma. The study was conducted in accordance with the GINA 2013 Guidelines, and the pharmacist interventions were individualised according to each participant's needs in asthma control. The findings of this study showed that the PharMS improved both the technique of using an inhaler and the medication adherence significantly. These led to better asthma control of the intervention participants. The PharMS also improved PEFR and reduced the usage of reliever medications. These findings are consistent with that reported by other pharmacy-based asthma management model in other countries (7-10,13,24-28). The results of GEE analysis, which showed a significant association between the PharMS and asthma control, further confirmed the effectiveness of the PharMS in improving asthma control. Two studies, one in a community pharmacy setting and another in a tertiary care hospital, also measured asthma control using the ACT score (8,13). Shanmugam et al. (13) found that pharmaceutical care program produced a positive impact in improving all the five ACT questions. On the contrary, Mehuys et al. (8) reported no change in the mean ACT scores from baseline for both study groups, but the ACT scores improved significantly in a subgroup analysis of patients with insufficiently controlled asthma at baseline. The present study did not perform a subgroup analysis of patients with uncontrolled asthma at baseline, but the overall results showed that both the difference in the ACT scores and the proportion of participants with controlled asthma at month 6 of the study were significant between the intervention and the control groups, with large effect sizes. Two studies (9,25) which measured asthma control with a clinically validated tool (Asthma Control Questionnaire) also reported significant improvement in asthma control. Other studies (10, 24, 28) that assessed pharmacist intervention on symptom control had also found significant improvement over the course of the study period.
Schatz et al. (29) showed that the minimum clinically important difference in the ACT scores was 3 points. A difference of 3 points in the ACT scores was associated with a subsequent 76% increased risk (95% CI, 73%-79%) of excess short-acting β-agonist use and a 33% increased risk (95% CI, 31%-35%) of exacerbations. In the present study, the difference in ACT scores between the intervention and the control groups at month 3 and 6 was 4.6 points. This implies that the improvement in asthma control with the PharMS is clinically significant. In the present study, the adjusted effect size of PEFR ratio was higher than that of PEFR at each visit, especially at month 6. This indicates that more participants had achieved or were approaching their expected PEFR in the intervention group although the improvement in PEFR at visit seemed small. The PEFR ratio allows more comprehensive comparisons and better interpretation of asthma control. However, none of the previous studies measured PEFR ratio. The improvement in PEFR at visit in this study was not significant. This is similar to the studies by Methuys et al. (8) and Abdelhamid et al. (24) . The studies which showed significant improvement in PEFR (13,28) had short follow-up period of not more than 3 months, younger age-group of participants with shorter asthma durations, unlike the present study which had a longer follow-up period of 6 months and participants of older age-group with an average of more than 25 years of asthma duration.
One of the criteria for better asthma control is the minimised use of reliever or rescue medication or absence of its use (5). This is supported by the present study and implies that the intervention arm had significantly better asthma control. These findings are consistent with that of other previous studies (7, 8, 24) .
Most patients with asthma were not able to use their inhalers correctly, and poor inhaler technique has been associated with poor asthma control (7, 25) . Optimal inhaler technique is essential for the medicines to reach the target organ and produce the required effects. In terms of controller medications, more effective control of airway inflammation can be achieved and hence, better asthma control (7) . The results of the present study showed that the PharMS Data are presented as frequency (%) with n = total number in each group; ACT = Asthma Control Test® (OptumInsight Life Sciences, Inc.); MALMAS = Malaysian Medication Adherence Scale (20) ; ¶ Fisher's Exact test was used for categorical variable with >20% of the expected count <5; NA = Not applicable. Chi square value, p-value and effect size were adjusted for clustering effects. *P<0.05; **P<0.01; ***Large effect size.
which included training on inhaler technique managed to significantly improve the proportion of participants who could use the inhaler correctly. In addition, the increase in this proportion was demonstrated from baseline to month 3 and 6 which indicates that regular monitoring and repeated training is probably required to ensure that patients are familiar with the correct technique of using their inhalers. Other studies also showed that both between-group and within-group had significant improvement in inhaler technique attributed to intervention (7) (8) (9) 26, 27) .
The present study showed that the proportion of participants who were adherent to their asthma medications was 47% higher than the control group, suggesting a beneficial impact of the intervention. This finding further demonstrated the importance of regular counselling and patient education on the necessity of controller (20) .
Gender, Age, Expected PEFR, PEFR ratio, Frequency, Indication were excluded in the model due to significant interactions. a = set to zero because this parameter is redundant. *P < 0.05; ** P < 0.01. medication (inhaled corticosteroid) and hence, improved medication adherence. Other previous studies which used validated self-reporting questionnaires also found significant improvement in medication adherence in the intervention group (7, 9, 25) . However, Mehuys et al. reported significant improvement in medication adherence using prescription refill rates but not via non-validated self-reporting method (8) .
Most participants from both control and intervention groups maintained the same medication profiles, such as the type, dose and frequency of the controller medications throughout the study period. This means that the improvement in asthma control would not be due to a change in the medications. The PharMS in the present study increased patients' adherence to their asthma medications as well as improved their inhaler technique.
The study had demonstrated an increase in knowledge on asthma medications in both control and intervention groups. The reassessments of medication knowledge at months 3 and 6 of the study period could have created a Hawthorne effect among participants in the control group. In addition, due to ethical reasons, the enumerators might have responded to the control participants' queries on the correct dose, frequency, indication and method of administration of their medications which led to some unavoidable contamination. However, the increase in the proportion of participants in the intervention group who had knowledge of these four parameters was significantly higher than in the control group. This could again be attributed to the comprehensive counselling sessions provided by the pharmacist in the PharMS.
There were several limitations in the present study. First, the number of clinics (only four clinics) included in this study was small, and hence, a bigger cluster size was required which led to a larger clustering effect (9) . However, analysis was done throughout the study period to ensure that the sample size was sufficient to detect the required significant differences in outcome measures between the control and the intervention groups. Second, the diagnosis of asthma did not include the use of a spirometer, as this was not available at the study sites. The physicians diagnosed asthma mainly based on the GINA Guidelines and the value of PEFR, using a peak flowmeter. Therefore, the possibility of some patients being misdiagnosed with asthma could not be ruled out although the World Health Organisation has listed peak flowmeter as an essential tool in the diagnosis of asthma and monitoring of treatment in settings with limited resources (30) .
The measure of patient knowledge on the dose, frequency, indication and method of administration of each asthma medication was not based on a validated instrument. Therefore, the reliability and validity of the results obtained could not be confirmed. All the participants recruited were using the same type of corticosteroid inhaler and reliever medication, both of which were in the form of MDI. Therefore, the results cannot be extrapolated to the use of other devices. The study was conducted in only two districts and hence the findings might not be generalizable to asthma patients in other parts of Malaysia. However, since the PharMS used in the present study has produced positive outcomes, this PharMS model can serve as a template for future studies or to improve routine clinical practice. Future studies should include more study sites throughout Malaysia to obtain a better representation of the Malaysia population with asthma.
Conclusion
A community-based asthma management program, the PharMS that provided asthma education and skill training via face-to-face counselling by a trained pharmacist, resulted in positive and significant improvements in clinical (asthma control) and management outcomes (inhaler technique, medication adherence, and patients' knowledge on asthma medications) of adult asthma patients. The need for patient-focused and patient-tailored care on the optimal use of asthma medications (via medication adherence and inhaler technique) have also been demonstrated in the present study. Therefore, the PharMS model should be considered for implementation in clinical practice. 
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